*(Note to writer: Be sure to include your name and address on both your letter and envelope, if you are mailing the letter.)*

**Date**

(Month) (Day), (Year)

**To Whom the Letter is Addressed**

The Honorable (First name) (Last name)

(Street Address)

(City), (State) (Zip Code)

**S.2706 – DIVERSE Trials Act**

**Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act or the DIVERSE Trials Act**

Dear Representative/Senator *(delete as appropriate, then insert Representative’s or Senator’s first name and last name)*:

My name is (your first and last name) and I am a resident in your district *(change ‘district’ to ‘state’ if speaking to a Senator)*.

I am aware of the critically growing issue of racial disparities in clinical trials. Specifically, current facts show that African American and Hispanic patients are almost nonexistent in cancer clinical trials for life-saving prescriptions that seek FDA approval. These trials are sponsored by pharmaceutical companies.1,2 Results from a published scientific study prove that when asked to participate, African American and Hispanic communities volunteer at comparable rates to Caucasians.3

*(If applicable, include a personal story. Tell your representative why the issue is important to you and how it affects you, your family members, and your community.)*

I believe it is important to work toward equality in healthcare for all Americans and to give people the chance to receive what could be life-saving therapies found in clinical trials.

With these points in mind, I am writing to request your support and sponsorship of the DIVERSE Trials Act (S.2706). This bill was introduced in the Senate on August 10, 2021.

Sincerely,

SIGN YOUR NAME

(Printed Name)

(Your Address)

(City), (State) (Zip Code)

**References:** **1.** Unger JM, Hershman DL, Osarogiagbon RU, et al. Representativeness of black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies. *JNCI Cancer Spectr*. 2020;4(4):pkaa034. doi:10.1093/jncics/pkaa034 **2.** Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. *JAMA Oncol*. 2019;5(10):e191870. doi:10.1001/jamaoncol.2019.1870 **3.** Unger JM, Hershman DL, Till C, et al. "When offered to participate": a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. *J Natl Cancer Inst*. 2021;113(3):244-257. doi: 10.1093/jnci/djaa155